Micromet Inc (MITI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micromet Inc (MITI)

MITI 0.120

+33.3%

12:18 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (149)	4/20/2010 1:02:23 PM
From: Arthur Radley	of 196

Needham & Company Reiterates a 'Buy' on Micromet (MITI); Positive Data Presentations at AACR of BiTE Platform 8:02 am ET 04/20/2010 - StreetInsider Needham & Company reiterates a 'Buy' rating on Micromet, Inc. (Nasdaq: MITI), price target $13. Needham analyst says, "We are impressed with the wide applicability of BiTE technology to generate and empower antibodies against a variety of well-validated tumor antigens...In the near-term, we believe the focus will be on blinatumomab, with upcoming expected events such as an EU pivotal study in ALL in mid-2010, additional trial initiations, and further data presentations. In the long-term, we believe the bispecific antibody platform as described above (7 products in development/12 candidates in early stage) will drive company growth." To see all the upgrades/downgrades on shares of MITI, visit our Analyst Ratings page. Micromet, Inc. (Micromet) is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next